TBPH on Nasdaq

Theravance Biopharma, Inc.

American pharmaceutical preparations company, incorporated in California. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ZEVRA THERAPEUTICS, INC., ImmunoGen Inc. or Zymeworks, or pick any stock.

  • TickerTBPH on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersGrand Cayman, California1
  • Incorporated inCA2
  • Business addressUgland House, South Church Street, George Town, Grand Cayman, Ca Ky1-11042
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Theravance Biopharma, Inc. (“we,” “our,” “Theravance Biopharma” or the “Company”) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference ® in people’s lives.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-3.4%Operating margin4
98.5%Net margin4
66.9%Revenue growth, 20254
35.7%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Collaborative revenue brought in 70% of the revenue Theravance Biopharma, Inc. broke down this way in fiscal 2025.

  1. Collaborative revenue$75.0M470%up 16% from 2024
  2. Milestone contingent consideration$25.0M423%
  3. License$7.5M47%
Products and services by year
Products and services20242025
Collaborative revenue$64.4M$75.0M
Milestone contingent consideration$25.0M
License$7.5M

Regions

United States brought in 70% of the revenue Theravance Biopharma, Inc. broke down this way in fiscal 2025.

  1. United States$75.0M470%up 16% from 2024
  2. Europe$32.5M430%
Regions by year
Regions20242025
United States$64.4M$75.0M
Europe$32.5M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development16¢$37.4M
  • Selling, general and admin31¢$73.7M
  • Income tax10¢$23.4M
  • Profit44¢$105.9M

Out of $107.5M in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$238.5M

Out of $238.5M of cash from operations.4

Financial statements

Revenue56784$107.5M in 2025+46% since 2019
0$50.0M$100.0M$150.0M2019: $73.4M$73.4M20192020: $71.9M$71.9M2020−2%2021: $55.3M$55.3M2021−23%2022: $51.3M$51.3M2022−7%2023: $57.4M$57.4M2023+12%2024: $64.4M$64.4M2024+12%2025: $107.5M$107.5M2025+67%
Operating income56784-$3.6M in 2025−99% since 2019
-$300.0M-$200.0M-$100.0M02019: -$251.9M-$251.9M20192020: -$297.6M-$297.6M2020+18%2021: -$257.8M-$257.8M2021−13%2022: -$92.0M-$92.0M2022−64%2023: -$56.0M-$56.0M2023−39%2024: -$46.9M-$46.9M2024−16%2025: -$3.6M-$3.6M2025−92%
Net income56784$105.9M in 2025
-$500.0M0$500.0M$1.0B2019: -$236.5M-$236.5M20192020: -$278.0M-$278.0M2020+18%2021: -$199.4M-$199.4M2021−28%2022: $872.1M$872.1M20222023: -$55.2M-$55.2M20232024: -$56.4M-$56.4M2024+2%2025: $105.9M$105.9M2025

Every line of the income statement as filed: the last 2 fiscal years (annual) or 8 quarters (quarterly), latest first.4

Period ending2025-12-312024-12-31
Total revenues$107.5M$64.4M
Research and development$37.4M$37.6M
Selling, general and administrative$73.7M$69.2M
Impairment of long-lived assets (non-cash)$0$4.5M
Total expenses$111.1M$111.3M
Loss from operations-$3.6M-$46.9M
Net gain on realized contingent milestone and royalty assets$75.1M
TRELEGY milestone income$50.0M
Interest expense (non-cash)-$2.5M-$2.5M
Interest and other income, net$10.2M$4.9M
Income (loss) before income taxes$129.2M-$44.6M
Provision for income tax benefit (expense)-$23.4M-$11.8M
Net income (loss)$105.9M-$56.4M
Net income (loss) per share - basic (in dollars per share)$2.10-$1.15
Net income (loss) per share - diluted (in dollars per share)$2.06-$1.15
Shares used to compute net income (loss) per share - basic (in shares)50.3M shares48.8M shares
Shares used to compute net income (loss) per share - diluted (in shares)51.5M shares48.8M shares
Share-based compensation expense$18.5M$21.4M

Compare Theravance Biopharma, Inc. with another company

Leadership

Who has led Theravance Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Rick E. Winningham2014–now

President

  1. Ann Brady2019–2022

Chief financial officer

  1. Renee D. Gala2015–2018
  2. Andrew A. Hindman2019–2022
  3. Aziz Sawaf2023–now
201520202025
Board members and other officers (33)

Timeline

  1. May 14, 2014New chief executive Rick E. Winningham becomes CEO12

Filings

427 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 73 major events, 228 insider forms, 42 large holders, 63 other. The latest 20:

  1. Oct 5, 202615-12G EDGAR
  2. Sep 28, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 25, 2026SCHEDULE 13D/A EDGAR
  4. Sep 24, 20264 EDGAR
  5. Sep 24, 20264 EDGAR
  6. Sep 24, 20264 EDGAR
  7. Sep 24, 20264 EDGAR
  8. Sep 24, 20264 EDGAR
  9. Sep 24, 20264 EDGAR
  10. Sep 24, 20264 EDGAR
  11. Sep 24, 20264 EDGAR
  12. Sep 24, 20264 EDGAR
  13. Sep 24, 20264 EDGAR
  14. Sep 24, 2026S-8 POS EDGAR
  15. Sep 24, 2026S-8 POS EDGAR
  16. Sep 24, 2026S-8 POS EDGAR
  17. Sep 24, 2026S-8 POS EDGAR
  18. Sep 24, 2026S-8 POS EDGAR
  19. Sep 24, 2026S-8 POS EDGAR
  20. Sep 24, 2026S-8 POS EDGAR

The 427 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 2 buys and 40 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 15, 2026Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale13,314$17.03$226.7KForm 4
Jul 7, 2026Samaha Eli10% ownerSale5,564$17.17$95.5KForm 4
Jul 6, 2026Samaha Eli10% ownerSale1,400$17.04$23.9KForm 4
Jul 1, 2026Samaha Eli10% ownerSale37,799$17.00$642.6KForm 4
Jun 30, 2026Samaha Eli10% ownerSale25,027$17.13$428.7KForm 4
Jun 29, 2026Samaha Eli10% ownerSale273,871$17.23$4.7MForm 4
Jun 15, 2026Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale13,314$16.39$218.2KForm 4
Mar 16, 2026Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale31,067$13.96$433.7KForm 4
Dec 3, 2025Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale31,067$18.75$582.5KForm 4
Nov 26, 2025BROSHY ERANDirectorSale29,501$20.00$590.0KForm 4
Nov 11, 2025BROSHY ERANDirectorSale45,000$17.98$809.2KForm 4
Nov 11, 2025BROSHY ERANDirectorSale59,000$18.11$1.1MForm 4
Jul 14, 2025Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale10,000$11.39$113.9KForm 4
Jun 2, 2025Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale24,000$11.00$264.0KForm 4
Apr 21, 2025Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale4,000$9.00$36.0KForm 4
Jan 21, 2025Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale4,000$9.00$36.0KForm 4
Nov 11, 2024Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale4,000$9.00$36.0KForm 4
Aug 7, 2024Samaha Eli10% ownerBuy999,800$7.80$7.8MForm 4
Jul 10, 2024Farnum RhondaSVP, COMM & MEDICAL AFFAIRSSale4,000$9.00$36.0KForm 4
May 1, 2024Samaha Eli10% ownerBuy1,499,124$8.75$13.1MForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 24, 2025George WhitesidesDemocratic, HouseSale$15,001 - $50,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61